 |
 |
There seems to be some confusion about this which I can help to clarify. The trade name is the name individual drug companies use to market a = generic drug. The generic name of the drug is carbidopa-levodopa which = is what we PD people need. It has been marketed as Sinemet(that is its = trade name) by the Merck Sharp and Dohme company. MSD had the original = patent for this drug, so it couldn't be marketed by any other company = until the patent expired. =20 Here in Australia two other companies have recently started marketing = carbidopa-levodopa at cheaper prices. They are called Kinson(marketed = by drug company Alphapharm) and Sinacarb(marketed by drug company = Amrad). Carbidopa-levodopa prescriptions are subsidised by the = Australian government so that pensioners pay $2-70 for 100 tablets and = others pay $17-40 (for the same number of tablets). However if you opt = for Sinemet rather than one of the other two drugs your pharmacist will = charge a premium of about $2-00, that's because MSD charge more for = their brand of Carbidopa-levodopa than the other two companies. It is = important to remember that all three brands(Sinemet, Kinson and = Sinacarb) are exactly the same generic drug carbidopa-levodopa. And by = the way Sinacarb 100/25 and Kinson 100/25 even look like = Sinemet100/25(yellow oval shaped tablet). One more slighly confusing = thing to note is that there is no 100/10 or 250/25 strength of Kinson. =20 Hope this is clear Seamus Tuohy ([log in to unmask])